norethindrone
PrintTrade Name(s): Norethindrone Acetate; Aygestin; Camila; Deblitane; Errin; Heather; Incassia; Jencycla; Lyleq; Lyza; Nora BE; Sharobel; Tulana | |
Group 2: Non-Antineoplastic Hazardous | AHFS Class: Progestins |
Preparation:
In-Cell Hazardous Drug
Activity | Gloves | Gown | Eye/Face | Notes/Instructions |
Dispensing prepackaged formulations |
| |||
Counting/Repackaging tablets and capsules | Recommended if pregnant, breast feeding or trying to conceive |
|
Administration:
In-Cell Hazardous Drug
Formulation | Gloves | Gown | Eye/Face | Notes/Instructions |
Tablets and capsules | (If patient requires assistance) | (If patient requires assistance) |
| |
Topicals, creams, vaginal rings | (If patient requires assistance) | (If patient requires assistance) |
|
Receiving and Storage:
Storage & Handling
Type of Instance | Gloves | Gown | Mask | Eye/Face | Notes/Instructions |
Receiving undamaged HD shipping container |
| ||||
Receiving damaged HD shipping container | If container must be opened | If container must be opened | If container must be opened |
| |
Spill Cleanup | Large volume | Large volume |
|
Reference: USP <800>
Disposal:
Disposals - All
Hazardous Pharmaceutical | Trace Chemo | Biohazardous and Sharps |
1. Non-returnable hazardous, chemo and EPA regulated drugs. (Patient specific prescriptions, partially used blister packs, containers with more than 3% medication remaining) 2. Empty bottles or packaging of P-Listed drugs. (Warfarin, nicotine, epinephrine, nitroglycerin, physostigmine) 3. PPE with visible contamination from hazardous drug. | 1. Waste contaminated through contact with chemotherapeutic agents. (Empty vials, IV bags, syringes and tubing) 2. PPE worn while handling hazardous drugs with NO visible contamination. (Gowns, gloves and masks) 3. Used CSTD devices. | 1. All sharps capable of cutting or piercing the skin. (Needles/syringes, broken ampules, lancets) 2. Items contaminated with blood or other potentially infectious materials. (Tubing, bags or dressings containing blood, contaminated waste from isolation patients) |
Transport:
Transporting
Dosage Form | Ship to Institution or Pharmacy | Ship to Locations Outside of ODOC |
Tablets and Capsules |
|
|
Liquid, Topical, and Transdermal |
|
|
PPE:
PPE Standards
PPE | Standards |
Shoe Covers |
|
Gowns |
|
Gloves |
|
Face Shields |
|
Goggles |
|
N95 Masks |
|
Removal and Disposal |
|
Reference: USP <800>
Assessment of Risk:
Exposure Risk:
- Suspected of causing cancer.
- May damage fertility or the unborn child.
Reference: PubChem
Mechanism of Action:
Progestins diffuse freely into target cells and bind to the progesterone receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.
Reference: Drug Bank
Safety Data Sheet(s):
Approved on January 8, 2024